Q&A: Medicinal microbiota

Two microbiologists speculate about the possibilities for developing therapeutics that affect human microbial communities

| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share
The human microbiota -- the communities of commensal bacteria that live in our gut, mouth, and on our skin -- have recently been hailed as a linkurl:forgotten organ,;http://www.nature.com/embor/journal/v7/n7/full/7400731.html and praised for the positive impact they have on our health. Recent research has suggested that the 1014 or so organisms, representing more than linkurl:500 species,;http://www.ncbi.nlm.nih.gov/pubmed/15894105 influence ailments such as inflammatory bowel disease, obesity, asthma and type I diabetes. The Scientist spoke with linkurl:Justin Sonnenburg;http://med.stanford.edu/profiles/microimmuno/researcher/Justin_Sonnenburg/ and linkurl:Michael Fischbach,;http://www.fischbachgroup.org/ microbiologists from Stanford University and the University of California San Francisco respectively, about potential therapeutics that target the human microbiota, the subject of a perspective linkurl:piece;http://stm.sciencemag.org/content/3/78/78ps12.abstract they authored, published today (April 13) in Science Translational Medicine.The Scientist: What is the fundamental idea behind using microbiota in medicine?
Michael Fischbach (left) and Justin Sonnenburg
Images: Courtesy of respective subjects
Justin Sonnenburg: The microbiota appear to relate to everything. This isn't at all startling as soon as you start to realize that the microbiota is wired into facets of immune regulation, metabolism, aspects of the nervous system. You would basically not expect a facet of human biology not to be influenced in some either direct or indirect way by what the microbiota is doing.Michael Fischbach: If we allow ourselves to think a little bit freely, one might imagine the differences in the composition of these microbiota that you see between healthy people and, say, people with Crohn's disease or one of the other inflammatory bowel diseases. Whether or not that difference is a cause or a consequence of the disease, you can imagine that fixing it would help treat at least the symptoms of the condition.TS: How might the microbiota be manipulated for human health benefits?JS: The concept of gene therapy has been around for quite a while and it is fairly evident that we should think about these microbes and their collected genome as an extended portion of our own genome. Since there's some plasticity in this community, in terms of being able to change and modulate what the genes are doing and what genes are present by changing community membership, we can actually leverage this plasticity in ways that we can't for the human genome. MF: I think that, for a long time, pharmaceutical companies or biotechnology companies who have been thinking about developing drugs that relate to bacteria have always been thinking about killing them. What I suspect will happen in the coming years is that people will begin realizing that they can design a drug that's targeted to bacteria living on or inside of us that is not meant to kill them. In some cases it could be meant to help them grow, in other cases it could be meant to change their function, maybe to induce them to produce a molecule that they otherwise would not have produced, or perhaps to get them to help break down fat or cholesterol or something else that we don't want to have around in our gut. There are lots of thing you can imagine trying to do with a drug that wouldn't be killing these bacteria.I think it's the realization that, in the same way that we think of drug targets that are encoded by the human genome, we should think about the microbiome as encoding a huge number of drug targets and ask the question, What would happen if we modulate these drug targets? TS: These surely are communities of bacterial and, as such, could effecting even one change alter their entire structures?
Bacteroides fragilis, an obligate gut microbe
Image: CDC
JS: That gets to one the concept of microbial ecology and whether we can take a systems view of the microbiota and learn how, for instance, addition of a single polysaccharide or a single organism may cause ripples that affect other community members indirectly through metabolic links and other sorts of interactions.MF: It is the case that there are very few perturbations you can make that won't, as Justin said, ripple through the community. Mapping changes in community composition to what's really important, the changes in function, is going to be the next big question.J.L. Sonnenburg and M.A. Fischbach, "Community Health Care: Therapeutic Opportunities in the Human Microbiome," Science Translational Medicine, 3(78), doi: 10.1126/scitranslmed.3001626, 2011.
**__Related stories:__*** linkurl:Gut microbes influence behavior;http://www.the-scientist.com/news/display/57968/
[31st January 2011]*linkurl:New gut bacteria regulate immunity;http://www.the-scientist.com/news/display/57901/
[23rd December 2010]*linkurl:Same poop, different gut;http://www.the-scientist.com/news/display/57795/
[3rd November 2010]
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Hannah Waters

    This person does not yet have a bio.
Share
Image of a woman in a microbiology lab whose hair is caught on fire from a Bunsen burner.
April 1, 2025, Issue 1

Bunsen Burners and Bad Hair Days

Lab safety rules dictate that one must tie back long hair. Rosemarie Hansen learned the hard way when an open flame turned her locks into a lesson.

View this Issue
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Pairing Protein Engineering and Cellular Assays

Pairing Protein Engineering and Cellular Assays

Lonza
Faster Fluid Measurements for Formulation Development

Meet Honeybun and Breeze Through Viscometry in Formulation Development

Unchained Labs
Conceptual image of biochemical laboratory sample preparation showing glassware and chemical formulas in the foreground and a scientist holding a pipette in the background.

Taking the Guesswork Out of Quality Control Standards

sartorius logo

Products

Sapio Sciences logo

Sapio Sciences Introduces Biorepository Management Solution 

Metrion Biosciences Logo

Metrion Biosciences launches NaV1.9 high-throughput screening assay to strengthen screening portfolio and advance research on new medicines for pain

Biotium Logo

Biotium Unveils New Assay Kit with Exceptional RNase Detection Sensitivity

Atelerix

Atelerix signs exclusive agreement with MineBio to establish distribution channel for non-cryogenic cell preservation solutions in China